Date: 2016-05-16
Type of information: R&D agreement
Compound:
Company: Johns Hopkins University (USA - MD) Sanofi Genzyme (USA - MA), a Sanofi company (France)
Therapeutic area: Neurodegenerative diseases
Type agreement: R&D
Action mechanism:
Disease: multiple sclerosis
Details: * On May 16, 2016, Sanofi Genzyme, the specialty care global business unit of Sanofi, announced a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression. Sanofi Genzyme’s MS research pipeline includes collaborations with academic medical centers that explore the pathogenesis of MS and potential novel therapeutics. Initiatives include identifying biomarkers of disease progression and exploring strategies to address neurodegeneration, considered to be a key factor driving disability accumulation in MS.
Financial terms:
Latest news:
